934180-47-9

Usage

Uses

Used in Pharmaceutical Industry:
2-Methyl-3-(trifluoromethyl)phenol is used as a pharmaceutical intermediate for the synthesis of various pharmaceutical products. Its unique chemical structure allows it to be a key component in the development of new drugs and medications.
Used in Chemical Industry:
2-Methyl-3-(trifluoromethyl)phenol is used as a synthetic building block for the production of dyes, pigments, and other specialty chemicals. Its versatility and reactivity make it a valuable asset in the chemical industry for creating a wide range of products.
Used in Research and Development:
2-Methyl-3-(trifluoromethyl)phenol is used as a research compound for studying its properties and potential applications in various fields. Its unique structure and reactivity make it an interesting subject for scientific investigation and the development of new technologies.

Upstream product

• 863111-55-1 1-iodo-2-methyl-3-(trifluoromethyl)benzene 
• 1338215-42-1 trimethyl[2-(2-methyl-3-trifluoromethylphenoxy)ethyl]silane 

Downstream Products

• 1151419-13-4 2-(2-methyl-3-trifluoromethyl-phenoxy)-butyronitrile 

Relevant academic research and scientific papers

2-(Trimethylsilyl)ethanol as a new alcohol equivalent for copper-catalyzed coupling of aryl iodides

2-(Trimethylsilyl)ethanol as a new alcohol equivalent has been employed for copper-catalyzed coupling of aryl iodides. Using mild reaction conditions, it has been observed that substituted phenols and phenols with sensitive functional groups can be readily prepared.

9-AZABICYCLO [3 . 3 . 1] NONANE DERIVATIVES AS MONOAMINE REUPTAKE INHIBITORS

The present invention relates to a 9-azabicyclo[3.3.1]nonane derivative of formula (I), wherein R1 is H or C1-5alkyl; X is O or NR2, wherein R2 is H, C1-5alkyl or C2-5acyl and Ar is C6-10aryl or a 5-10 membered heteroaryl ring system, both being optionally substituted with one to three of R3-R5 independently selected from halogen, C1-5alkyl, C1-5alkoxy, C3-6cycloalkyl, C2-5alkenyl, C2-5alkynyl, CN, NO2, hydroxy, phenyl, phenoxy and phenylC1-2alkoxy, wherein said C1-5alkyl and C1-5alkoxy are optionally substituted with one to three halogens and wherein said phenyl, phenoxy and phenylC1-2alkoxy are optionally substituted with one to three substituents independently selected from halogen and methyl or two of R3-R5 at adjacent positions together form a methylenedioxy or propylene unit, with the proviso that the compounds exo-9-methyl-3-phenoxy-9-azabicyclo[3.3.1]nonane and N-(9-methyl-9-azabicyclo[3.3.1]non-3-yl)-1H indazole-5-amine are excluded, or a pharmaceutically acceptable salt or solvate thereof. The invention also relates to pharmaceutical compositions comprising said 9-azabicyclo[3.3.1]nonane derivatives and to their use in therapy.